New Wegovy pill offers needle-free weight loss — but may not work for everyone

The first-ever oral GLP-1 medicine for value nonaccomplishment has been approved for usage successful the U.S.

The Wegovy pill, from drugmaker Novo Nordisk, was cleared by the Food and Drug Administration to trim excess assemblage weight, support semipermanent value simplification and little the hazard of large cardiovascular events.

Approval of the once-daily 25mg semaglutide pill was based connected the results of 2 objective trials — the OASIS proceedings programme and the SELECT trial.

WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS

The Wegovy pill demonstrated a mean value nonaccomplishment of 16.6% successful the OASIS 4 proceedings among adults who were obese oregon overweight and had 1 oregon much comorbidities (other aesculapian conditions), according to a property release. In the aforesaid trial, 1 successful 3 participants experienced 20% oregon greater value loss.

The first-ever oral GLP-1 medicine for value nonaccomplishment has been approved for usage successful the U.S. (iStock)

Novo Nordisk reported that the value nonaccomplishment achieved with the pill is akin to that of injectable Wegovy and has a akin information profile.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS' LIVES, RESEARCHERS PROJECT

"With today's support of the Wegovy pill, patients volition person a convenient, once-daily pill that tin assistance them suffer arsenic overmuch value arsenic the archetypal Wegovy injection," said Mike Doustdar, president and CEO of Novo Nordisk, successful the property release.

Novo Nordisk reported that the value nonaccomplishment achieved with the pill is akin to that of injectable Wegovy and has a akin information profile. (James Manning/PA Images via Getty Images)

"As the archetypal oral GLP-1 attraction for radical surviving with overweight oregon obesity, the Wegovy pill provides patients with a new, convenient attraction enactment that tin assistance patients commencement oregon proceed their weight-loss journey."

POPULAR WEIGHT-LOSS DRUGS COULD TAKE THE EDGE OFF YOUR ALCOHOL BUZZ, STUDY FINDS

The oral GLP-1 is expected to motorboat successful the U.S. successful aboriginal January 2026. Novo Nordisk has besides submitted oral semaglutide for obesity to the European Medicines Agency (EMA) and different regulatory authorities.

"Most broadside effects volition beryllium GI-related and should beryllium akin to the injectable, specified arsenic nausea, vomiting and constipation," an adept said. (iStock)

Dr. Sue Decotiis, a aesculapian value nonaccomplishment doc successful New York City, confirmed successful an interrogation with Fox News Digital that studies amusement oral Wegovy is comparable to the play injectable, conscionable without the needles.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Although the pill whitethorn effect successful amended compliance and easiness of use, Decotiis warned that immoderate patients whitethorn not sorb the medicine done the gastrointestinal tract arsenic good arsenic with the injectable mentation owed to idiosyncratic idiosyncrasies successful the body.

"Most broadside effects volition beryllium GI-related and should beryllium akin to the injectable, specified arsenic nausea, vomiting and constipation," she said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"In my practice, I person recovered tirzepatide (Mounjaro and Zepbound) to output much value nonaccomplishment and abdominous nonaccomplishment than semaglutide by astir 20%," the doc added. "This has been shown successful studies, often [with] less broadside effects."

More oral GLP-1s whitethorn beryllium coming down the pike successful 2026, according to Decotiis, including an Orforglipron exertion by Lilly and a caller operation Novo Nordisk drug, which is pending support aboriginal adjacent year.

One adept warned that immoderate patients whitethorn not sorb the medicine done the gastrointestinal tract arsenic good arsenic with the injectable version. (iStock)

"There volition beryllium much caller drugs disposable successful the aboriginal that volition beryllium much effectual for patients who are much insulin-resistant and person not responded arsenic good to semaglutide and/or tirzepatide," the doc said. "This is large news, arsenic caller drugs affecting much receptors mean amended semipermanent results successful much patients."

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

As these medications go cheaper and easier to access, Decotiis emphasized that keeping up with steadfast manner habits — including due nutrition with capable macromolecule and fiber, arsenic good arsenic accrued hydration — is indispensable to ensuring lasting results.

CLICK HERE FOR MORE HEALTH STORIES

"If not, patients volition regain value and could suffer musculus and not capable assemblage fat," she said.

Fox News Digital reached retired to Novo Nordisk for comment.